Intended for healthcare professionals


Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials

BMJ 2016; 352 doi: (Published 14 March 2016) Cite this as: BMJ 2016;352:i1525

In figure 3 the number of participants with myocardial infarction in the RAS blockers group of the STOP-2 trial is missing (BMJ 2016;352:i438, doi:10.1136/bmj.i438). The data for that group should show that 17 participants out of 235 (17/235) had an outcome of myocardial infarction.

View Abstract